CSCs were first identified in acute myeloid leukemia (AML); the study demonstrated that AML CSCs with the phenotype CD34+ CD38− constituting approximately 0.1–1% of the tumor population, can generate AML in mice [2]. This evidence concerns the gene CD34 and acute myeloid leukemia.